Rate of delivery of hyperbaric oxygen treatments does not affect response in soft tissue radionecrosis.
|
|
- Jared Martin
- 5 years ago
- Views:
Transcription
1 Rate of delivery of hyperbaric oxygen treatments does not affect response in soft tissue radionecrosis. Submitted - 2/23/07; Accepted 4/23/07 N. B. HAMPSON 1, J. M. CORMAN 2 1 Center for Hyperbaric Medicine, Section of Pulmonary and Critical Care Medicine; 2 Section of Urology and Renal Transplantation, Virginia Mason Medical Center, Seattle, Washington Hampson NB, Corman JM. Rate of delivery of hyperbaric oxygen treatments does not affect response in soft tissue radionecrosis. Undersea Hyperb Med 2007; 34(5): Background: Soft tissue radiation necrosis (STRN) is effectively treated with hyperbaric oxygen (HBO 2 ), believed to result from stimulation of angiogenesis in radiation-injured tissue. Thirty to forty HBO 2 treatments are usually recommended for STRN. For various reasons, different hyperbaric facilities offer these treatments once or twice daily and from 5-7 days weekly. It is not known whether the clinical response differs as a result of the rate of administration of HBO 2 treatments. Methods: Details of hyperbaric treatment courses of patients treated for radiation enteritis/proctitis (n=65) and cystitis (n=94) at a single institution were reviewed. Outcomes were compared with the total number of HBO 2 treatments administered and also rate of treatment administration. Results: Responses were similar for both forms of STRN whether the patient averaged fewer or greater than 5 treatments per week, or even < 3 versus > 7 treatments weekly. Outcome did differ, however, dependant on the total number of treatments administered. Response was better in patients receiving 30 or more total treatments, as compared with fewer. Conclusions: Soft tissue radionecrosis of the gastrointestinal tract or bladder is (1) effectively treated with hyperbaric oxygen, (2) has a higher response rate if at least 30 treatments are administered, and (3) is equally responsive to rates of hyperbaric treatment ranging from 3 or fewer to 7 or more treatments per week. INTRODUCTION Hyperbaric oxygen (HBO 2 ) therapy is effective treatment for many forms of chronic radiation tissue injury. Both soft tissue radiation necrosis (STRN) and osteoradionecrosis are indications accepted by the Undersea and Hyperbaric Medical Society for hyperbaric oxygen treatment (1). In a recent evidencebased review by Feldmeier and Hampson, STRN at numerous sites in the body was found to be effectively managed with HBO 2 treatment (2). The pathophysiology of chronic radiation tissue injury involves fibrosis and endarteritis leading to loss of capillary density and resultant tissue hypoxia (3). HBO 2 is felt to be effective in STRN by enhancing angiogenesis and, in so doing, providing oxygen to meet the metabolic demands of radiation injured tissues. Marx has shown a dose dependent increase in vascular density in irradiated animals treated with hyperbaric oxygen (4). The exact mechanism by which this occurs is not completely understood but is under investigation. Clinically, STRN is treated with HBO 2 using protocols that range in maximum pressure from 2.0 to 2.5 atmospheres absolute (atm abs) and in oxygen breathing time from 90 to 120 minutes (1). Patients typically receive 30 to 40 treatments, delivered 5, 6 or 7 days weekly and once or twice daily, depending upon the staffing and physical capacity of the hyperbaric treatment facility involved. Copyright 2007 Undersea and Hyperbaric Medical Society, Inc 329
2 No studies exist to determine whether the rate of delivery of hyperbaric treatments influences outcome in chronic radiation tissue injury. While treatment approaches differ between facilities, it remains unknown whether administration of varying numbers of treatments per day or per week is equivalent therapy. This study was performed to analyze outcomes in two forms of STRN, radiation enteritis/proctitis and hemorrhagic radiation cystitis, with regard to rate of administration of HBO 2 therapy. METHODS We have previously reported outcomes in patients treated with HBO 2 at Virginia Mason Medical Center (VMMC) in Seattle, for STRN of the gastrointestinal tract and bladder (5,6,7). With regard to radiation-induced enteritis/proctitis, 65 consecutive patients ranging in age from years (median 65 years) and treated with HBO 2 from were reviewed and reported. They are the population used for analysis of response of STRN of the bowel to varying rates of HBO 2 administration in the present study. To briefly summarize that experience, patients received from HBO 2 treatments (median 30 treatments). Outcomes were retrospectively graded by an independent records reviewer not associated with administration of the hyperbaric treatment and categorized as (1) complete response (greater than 90% reduction in symptom frequency or subjective symptom complaints and endoscopic documentation of healing when available), (2) partial response (50-90% reduction in symptom frequency or subjective measure of improvement and endoscopic documentation of improvement), or (3) failure (less than 50% measurable or subjective improvement, minimal or no endoscopic improvement or the need for surgical intervention). Outcomes from hyperbaric treatment are shown in Table 1. Response Category Radiation Enteritis/Proctitis (n=65) Radiation Cystitis (n=94) Complete 43% (n=28) 40% (n=38) Partial 25% (n=16) 43% (n=40) Failure 32% (n=21) 17% (n=16) Table 1. Outcomes of patients with radiation-induced enteritis/proctitis and radiation cystitis treated with hyperbaric oxygen. In 2003, outcomes in 62 consecutive patients with hemorrhagic radiation cystitis treated with HBO 2 at VMMC from were reported. As above, retrospective review was performed by an independent reviewer and patient outcomes categorized as (1) complete (resolution of hematuria), (2) partial (marked improvement in hematuria), or (3) failure (unchanged or worsened hematuria) following HBO 2 treatment. Since that time, 32 additional patients were treated through 2006 and are combined with the previous group for the present analysis. The study population with STRN of the bladder thus includes 94 consecutive patients ranging in age from years (median 74 years) and receiving from 4-60 HBO 2 treatments (median 30 treatments). Outcomes following hyperbaric treatment are also shown in Table 1. See the respective publications for the full details of methods and results of these initial studies (5,6,7). At VMMC, patients with STRN are offered once or twice daily hyperbaric treatment from Monday through Friday and once daily on Saturday and Sunday, scheduled at their discretion. Within this construct, they attend treatment from 0-12 times weekly, depending on their own circumstances. For the present analysis, treatment records were reviewed to determine the date of each patient s first and last hyperbaric treatments, The total number of days encompassed in the course were counted, divided into total number of treatments that the patient received to obtain an average treatment per day rate. Average treatment per week (per 7 days) rate was then calculated from this. 330
3 To determine whether rate of treatment was associated with outcome, number of responders (partial plus complete, as defined above) vs. nonresponders (failure) for each of the two sites and then both sites combined were compared with regard to those receiving an average of 5 or fewer treatments per week and more than 5 treatments per week (2 x 2 contingency table, Fisher s Exact Test). The same analysis was then repeated with regard to those receiving an average of 3 or fewer treatments per week with those who received 7 or more treatments per week. Finally, outcome with regard to total number of treatments received independent of rate was analyzed by comparing responders vs. nonresponders among those who received fewer than 30 treatments with those who received 30 or more total treatments. RESULTS Hyperbaric treatment courses for patients treated for radiation enteritis/proctitis ranged from days (median 43 days). Individual patients averaged from 1-13 treatments per week over their course of therapy (median 5 treatments per week). Treatment courses for those with radiation cystitis ranged from days (median 44 days) and averaged from 2-12 treatments per week (median 5 treatments per week). Patients treated more than 5 times weekly typically were from out of town and staying with friends, relatives or at a hotel. They tended to be more interested in accelerated therapy. Patients with prolonged treatment courses either had other medical issues which needed to be addressed during their course of hyperbaric therapy or were poorly compliant with attendance for personal reasons. Among patients treated for radiation enteritis/proctitis, radiation cystitis, or both combined, there were no significant differences between those averaging 5 or fewer treatments per week compared with those averaging over 5 treatments per week (Table 2a; p = , , and , respectively). There were also no significant differences in outcome for the same groups between those averaging 3 or fewer treatments per week when compared with those averaging 7 or more treatments per week (Table 2b; p = , , and , respectively). When comparing those who received fewer than 30 total hyperbaric treatments with those who received 30 or more total treatments, the response rate was significantly greater in the latter Table 2-a Table 2-b Table 2. Contingency tables for patients treated for radiation enteritis/proctitis, radiation cystitis, or both conditions combined, comparing (a) those who averaged 5 or fewer HBO 2 treatments per week with those averaging greater than 5 treatments per week, and (b) those who averaged 3 or fewer HBO 2 treatments per week with those averaging 7 or more treatments per week (Fisher s Exact Test). 331
4 Table 3. Contingency tables for patients treated for radiation enteritis/proctitis, radiation cystitis, or both conditions combined, comparing those who fewer than 30 total HBO 2 treatments with those who received 30 or more total treatments (Fisher s Exact Test). group for patients treated for radiation enteritis/ proctitis, radiation cystitis, or both conditions combined (Table 3; p = , , and , respectively). The number of responding and nonresponding patients with varying numbers of total HBO 2 treatments is shown in Figure 1. Number of Patients Fig. 1. Number of responders and nonresponders to various numbers of HBO 2 treatments. DISCUSSION Over one million new cases of invasive cancer are diagnosed annually in the United States and approximately one-half of those patients receive radiation therapy as part of the management of their malignancy (8). While long-term complications occur in fewer than 5% of patients and are therefore relatively rare (3), the number of patients treated yields the potential for many cases of chronic radiation tissue injury or necrosis Number of HBO2 Treatments Responder 48 Nonresponder As noted, HBO 2 has been shown to be effective treatment for many types of chronic radiation injury. In their evidence-based review, Feldmeier and Hampson combined the results of published series and found hyperbaric treatment response rates of 96% for radiation enteritis/ proctitis (36 resolved, 60% improved) and 76% for radiation cystitis (2). When the enteritis/ proctitis evidence was graded by the American Heart Association scheme, the results were felt to support an AHA IIb indication category ( fair to good evidence provides support ). The results of radiation cystitis series were so consistent that a Class IIa AHA designation was assigned ( acceptable and useful ). Further, hyperbaric treatment for soft tissue radionecrosis is covered by Medicare and most third-party payors. HBO 2 is widely used for treatment of STRN both in the US and internationally. While treatment pressures and oxygen breathing times do vary, they are relatively similar from facility to facility. A bigger difference, and one with more impact on patient access to care, is the rate that treatments are administered. From a facility standpoint, availability of once vs. twice daily treatment is often controlled by chamber capacity issues. The number of days that a facility provides non-emergent treatment weekly is usually governed by staffing and budgetary issues. From a patient standpoint, many desire to complete their prescribed course of treatment as rapidly as possible. This is particularly true for patients who live a long distance from the 332
5 hyperbaric facility. If they commute daily, many prefer to complete two treatments per day, if possible. If they live too far to commute and must pay for local housing, most are anxious to expedite therapy, minimize costs for housing, and return home to their families and jobs as soon as possible. Until now, there have been no published data to guide the decision of rate of therapy. Although the mechanism of HBO 2 -induced angiogenesis in irradiated tissue is not completely understood, there is presumably some stimulus produced by the hyperbaric exposure, followed by a period of metabolic response. No animal studies have examined whether equivalent angiogenesis is produced by once and twice daily treatment. In clinical discussions of once vs. twice daily treatment, the question is usually raised as to whether there is sufficient time for the metabolic response necessary for angiogenesis to occur if the treatments are administered twice daily. The present study demonstrates that the rate of hyperbaric treatment does not influence the therapeutic outcome for two forms of STRN. Forty HBO 2 treatments delivered in 20 days should be expected to induce the same therapeutic response as 40 treatments delivered in 60 days. It is also demonstrated that response is not simply a function of days of treatment. Twenty treatments in 20 days would not be expected to yield the same outcome as 40 treatments in 20 days. Patient response for both conditions correlated significantly with total number of treatments. Patients who received fewer than 30 treatments had a poorer response rate than those receiving 30 or more. The implications for clinical practice are many. First, a patient being treated for radiation enteritis/proctitis or cystitis should not be denied twice daily treatment out of concern for poorer outcome. If facility capacity with regard to chamber availability and staffing are adequate, twice daily treatment can be offered to those who desire it. Secondly, there does not appear to be a reason for concern if a patient prolongs treatment over a long period. Those who received 3 treatments or fewer per week did as well as those who completed 5, 7 or more weekly. As such, a patient s treatment should not be discontinued solely for the issue of infrequent attendance. Finally, from a facility standpoint, flexing patient treatment schedules from once to twice daily as capacity allows is an excellent method for leveling production and reducing costs by minimizing variation as represented by peaks and troughs in patient volume. In this analysis, total numbers of treatments fewer or greater than 30 were compared for efficacy because that was the median number administered. At the time patients were treated early in each series, 30 treatments were typically prescribed. It should be noted that 40 treatments is the number generally recommended now for soft tissue radionecrosis (1). In radiation cystitis for example, 40 hyperbaric treatments is the optimal number for both acute resolution of symptoms and a long-term durable result (9). Shorter treatment courses are associated with a higher incidence of relapse. The potential limitation to this study is the fact that the patients self-selected their own treatment rates and were not randomized to higher versus lower rates. Such a randomized trial would be quite difficult to accomplish. In our experience, even when patients are scheduled for once or twice daily treatment, they rarely complete their entire course of therapy exactly on schedule. In fact, as evidenced by the present data, the study performed is more real world than would be either arm of a randomized trial. Further, bias from self-selection should only be a concern if a difference had been demonstrated associated with treatment rate. To summarize, soft tissue radionecrosis of the gastrointestinal tract or bladder is (1) effectively treated with hyperbaric oxygen, (2) has a better response rate to therapy if at least 30 treatments are administered, and (3) is equally responsive to 333
6 rates of hyperbaric treatment ranging from 3 or fewer to 7 or more treatments per week. REFERENCES 1. Hyperbaric Oxygen 2003: Indications and Results: The Hyperbaric Oxygen Therapy Committee Report. Feldmeier JJ, Chairman and Editor. Kensington, MD: Undersea and Hyperbaric Medical Society, Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed radiation injuries: An evidence based approach. Undersea Hyperb Med 2002;29: Rubin P, Casarrett GW. Clinical Radiation Pathology, Vol 1. Philadelphia, PA: WB Saunders, 1968: Marx RE, Ehler WJ, Tayapongsak P, Pierce LW. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 1990;160: Dall Era MA, Hampson NB, Corman JM. Hyperbaric oxygen therapy for radiation-induced proctopathy in men with prostate cancer. J Urol 2006; 176: Marshall GT, Thirlby RC, Bredfeldt JE, Hampson NB. Treatment of gastrointestinal radiation injury with hyperbaric oxygen. Undersea Hyperb Med 2007; 34(1): Corman JM, McClure RD, Pritchett TR, Kozlowski P, Hampson NB. Treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen. J Urol 2003; 169: Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, CA Cancer J Clin 2002;52: Hendricks DM, Kraft KL, Moon RE, Piantadosi, CA, Stolp BW. Dose-response for hyperbaric oxygen treatment of radiation cystitis (abstract). Undersea Hyperb Med 2000;27(Suppl):
EARLY HYPERBARIC OXYGEN THERAPY IMPROVES OUTCOME FOR RADIATION-INDUCED HEMORRHAGIC CYSTITIS
ADULT UROLOGY EARLY HYPERBARIC OXYGEN THERAPY IMPROVES OUTCOME FOR RADIATION-INDUCED HEMORRHAGIC CYSTITIS KIAN TAI CHONG, NEIL B. HAMPSON, AND JOHN M. CORMAN ABSTRACT Objectives. To assess the clinical
More informationProspective Assessment of Outcomes in 411 Patients Treated With Hyperbaric Oxygen for Chronic Radiation Tissue Injury
Prospective Assessment of Outcomes in 411 Patients Treated With Hyperbaric Oxygen for Chronic Radiation Tissue Injury Neil B. Hampson, MD 1 ; James R. Holm, MD 1 ; Claude E. Wreford-Brown, CHRN 1 ; and
More informationFACULTY DISCLOSURE INFORMATION
HYPERBARIC OXYGEN AND THE CANCER PATIENT: WHAT ARE THE POSSIBILITIES FACULTY DISCLOSURE INFORMATION John J. Feldmeier, D.O.,FACRO, FUHM Professor Emeritus and Former Chairman Radiation Oncology University
More informationHyperbaric oxygen therapy for refractory radiation-induced hemorrhagic cystitis
International Journal of Urology (2015) 22, 962--966 doi: 10.1111/iju.12857 Original Article: Clinical Investigation Hyperbaric oxygen therapy for refractory radiation-induced hemorrhagic cystitis Tiago
More informationHyperbaric Oxygen and Wound Care Standards Michael Lusko, DO, FACEP - Board Certified HBO Physician, Medical Director - The Center for Wound Care and
Hyperbaric Oxygen and Wound Care Standards Michael Lusko, DO, FACEP - Board Certified HBO Physician, Medical Director - The Center for Wound Care and Hyperbaric Medicine, Baptist Medical Center Downtown
More informationHyperbaric oxygen treatment time for cyclophosphamide induced cystitis in rats.
Hyperbaric oxygen treatment time for cyclophosphamide induced cystitis in rats. E. OZTAS 1, A. KORKMAZ 2, S. OTER 2, T.TOPAL 2 1 Department of Medical Histology and Embryology, 2 Department of Physiology
More informationCarboxyhemoglobin levels in carbon monoxide poisoning: do they correlate with the clinical picture?
American Journal of Emergency Medicine (2008) 26, 665 669 www.elsevier.com/locate/ajem Original Contribution Carboxyhemoglobin levels in carbon monoxide poisoning: do they correlate with the clinical picture?
More informationHyperbaric Oxygen Therapy (HBO)
MP9055 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below None Prevea360 Health Plan Medical Policy: 1.0 Hyperbaric Oxygen therapy (HBO)
More informationfor Grade IV radiation-induced haemorrhagic cystitis. prospective pilot-feasibility study and review of literature
Review Article Vol. 40 (3): 296-305, May - June, 2014 doi: 10.1590/S1677-5538.IBJU.2014.03.02 Is there a role for hyberbaric oxygen as primary treatment for grade IV radiation-induced haemorrhagic? a prospective
More informationGOALS & OBJECTIVES 3/26/2012. Effects of Hyperbaric Oxygen on Tissue Altered by Radiation. Hyperbaric Oxygen Therapy
AMERICAN NURSES ASSOCIATION CENTER FOR CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT Required Disclosures to Participants Conflicts of Interest A conflict of interest occurs when an individual has
More informationEARLY HYPERBARIC OXYGEN THERAPY FOR REDUCING RADIOTHERAPY SIDE EFFECTS: EARLY RESULTS OF A RANDOMIZED TRIAL IN OROPHARYNGEAL AND NASOPHARYNGEAL CANCER
doi:10.1016/j.ijrobp.2008.11.056 Int. J. Radiation Oncology Biol. Phys., Vol. 75, No. 3, pp. 711 716, 2009 Copyright Ó 2009 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/09/$ see front
More informationUreteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor
Ureteroscopy Is Indicated in every patient with suspected Upper Tract Urothelial Tumor Scott G. Hubosky, MD The Demetrius H. Bagley Jr., MD Associate Professor of Urology Director of Endourology Vice Chair
More informationContinuous bladder irrigation in the monoplace hyperbaric chamber: Two case reports
Continuous bladder irrigation in the monoplace hyperbaric chamber: Two case reports Jeffrey S. Cooper, M.D. 1, Peter Allinson, M.D. 2, Dana Winn, BSN, R.N., CHRN 3, Lon Keim, M.D. 3, Joe Sippel, M.D. 3,
More informationThe Role of Hyperbaric Therapy in Wound Management
No Conflicts to declare No off label use discussed Define the role of oxygen as a signal molecule Understand the difference between oxygen pressure versus oxygen content Define the role of oxygen and the
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationHyperbaric Oxygen Utilization in Wound Care
Hyperbaric Oxygen Utilization in Wound Care Robert Barnes, MD, CWS Hyperbaric Center Sacred Heart Medical Center Riverbend Springfield, Oregon No relevant disclosures Diabetes and lower extremity wounds
More informationHyperbaric oxygen therapy for late radiation tissue injury (Review)
Hyperbaric oxygen therapy for late radiation tissue injury (Review) Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationHYPERBARIC OXYGEN THERAPY FOR LATE RADIATION TISSUE INJURY IN CERVICAL AND OTHER GYNECOLOGICAL MALIGNANCIES
HYPERBARIC OXYGEN THERAPY FOR LATE RADIATION TISSUE INJURY IN CERVICAL AND OTHER GYNECOLOGICAL MALIGNANCIES Date Developed: September, 2009 The recommendations contained in this guideline are a consensus
More informationYour Chemotherapy. The Common side effects are:
1 10 This information leaflet is designed to help you understand more about the treatment you have opted to undertake. You will be receiving both chemotherapy and radiotherapy that work together to treat
More informationDoes Hyperbaric Oxygen Administration Decrease Side Effect and Improve Quality of Life after Pelvic Radiation?
ORIGINAL ARTICLE Does Hyperbaric Oxygen Administration Decrease Side Effect and Improve Quality of Life after Pelvic Radiation? Suyanto Sidik*, Daldiyono Hardjodisastro**, Rianto Setiabudy***, Soehartati
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationHemorrhagic cystitis
Hemorrhagic cystitis Bradley Rosenberg, MD Assistant Professor of Urology Oakland University William Beaumont School of Medicine Comprehensive Urology Hemorrhagic cystitis Definition: Sustained hematuria
More information250 CASES OF CARCINOMA OF URINARY BLADDER A PRELIMINARY REVIEW
250 CASES OF CARCINOMA OF URINARY BLADDER A PRELIMINARY REVIEW Pages with reference to book, From 102 To 105 S. Adeebul Hassan Rizvi, S. Anwar Naqvi ( Department of Urology, Dow Medical College and Civil
More informationINTERSTITIAL CYSTITIS (IC) MANAGEMENT
INTERSTITIAL CYSTITIS (IC) MANAGEMENT About Interstitial Cystitis (IC) What is IC? IC is a chronic, yet manageable, bladder condition, characterized by bladder or pelvic pain, pain during or after sexual
More informationPulmonary Rehabilitation
Pulmonary Rehabilitation New Benefit The enactment of HR 6331, the Medicare Improvements for Patients and Providers Act of 2008, established a specific Medicare benefit for pulmonary rehabilitation. The
More informationThe influence of radiotherapy on osseointegration
Experience with Osseointegrated Implants Placed in Irradiated Tissues in Japan and the United States Atsushi Niimi, DDS, DMSc*/Minoru Ueda, DDS, PhD**/ Eugene E. Keller, DDS, PhD***/Philip Worthington,
More informationHYPERBARIC OXYGEN THERAPY IN THE TREATMENT OF RADIO-INDUCED LESIONS IN NORMAL TISSUES
HYPERBARIC OXYGEN THERAPY IN THE TREATMENT OF RADIO-INDUCED LESIONS IN NORMAL TISSUES CONSENSUS CONFERENCE Long Version Jointly held by: EUROPEAN SOCIETY FOR THERAPEUTIC RADIOLOGY AND ONCOLOGY AND EUROPEAN
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationHyperbaric oxygen therapy Villanueva E, Johnston R, Clavisi O, Burrows E, Bernath V, Rajendran M, Wasiak J, Fennessy P, Anderson J, Harris A, Yong K
Hyperbaric oxygen therapy Villanueva E, Johnston R, Clavisi O, Burrows E, Bernath V, Rajendran M, Wasiak J, Fennessy P, Anderson J, Harris A, Yong K Authors' objectives To assess the effectiveness of hyperbaric
More informationTreatment of Graves Disease by the Atomic Cocktail by Malcolm R. Powell, M.D., F.A.C.P, F.A.C.N.P
GRAVES DISEASE FOUNDATION Educate * Encourage * Empower 400 International Drive Williamsville, NY 14221 (877) 643-3123 Treatment of Graves Disease by the Atomic Cocktail by Malcolm R. Powell, M.D., F.A.C.P,
More informationAnnouncement of a New Treatment Protocol for Autism Spectrum Disorders and other Neurological Impairments
Testimony Announcement of a New Treatment Protocol for Autism Spectrum Disorders and other Neurological Impairments The International Hyperbaric Medical Association Foundation Paul Harch, M.D. President
More informationHyperbaric oxygen therapy in the treatment of complications of irradiation in head and neck area.
Hyperbaric oxygen therapy in the treatment of complications of irradiation in head and neck area. W. NAROZNY 1, Z. SICKO 2, J. KOT 2, C. STANKIEWICZ 1, T. PRZEWOZNY 1, J. KUCZKOWSKI 1 1 ENT Department
More informationProduct: Femmerol. Client: Solutions for Women, LLC 315 North Village Avenue New York, (516)
CLINICAL TRIAL In 2002 the company completed an IRB (Institutional Review Board) Prospective, Randomized, Placebo-Controlled Clinical Trial. In Conclusion: Femmerol is effective in relieving a number of
More informationSimulating Potential Layouts for a Proton Therapy Treatment Center
Simulating Potential Layouts for a Proton Therapy Treatment Center Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil- American University Howard Zhang- University of
More informationRapid Recovery Hyperbarics 9439 Archibald Ave. Suite 104 Rancho Cucamonga CA,
Research on Long Term Multiple Sclerosis (MS) The Federation of Multiple Sclerosis Therapy Centres provide hyperbaric oxygenation (HBO) for the treatment of Multiple Sclerosis. This report follows the
More informationIntroduction to clinical Radiotherapy
Introduction to clinical Radiotherapy Sarah Brothwood Radiotherapy Practice Educator Rosemere Cancer Centre Sarah.brothwood@lthtr.nhs.uk 01772 522694 Radiotherapy We have been able to see and document
More informationProton or Photon RT for Retroperitoneal Sarcomas
Principle Investigator Thomas F. DeLaney, M.D. Contact Additional Info Institution Thomas DeLaney, MD 617-726-6876 tdelaney@partners.org www.clinicaltrials.gov NCT01659203 Massachusetts General Hospital
More informationRADIATION INDUCED SMALL BOWEL DISEASE. Dr Mnguni Supervisor: Dr Lohlun Radiation Oncology
RADIATION INDUCED SMALL BOWEL DISEASE Dr Mnguni Supervisor: Dr Lohlun Radiation Oncology INTRODUCTION Radiation therapy is not regularly indicated in the treatment of small bowel disease. Reasons are complex
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationLearn how to JUMPSTART YOUR IMMUNE SYSTEM
Learn how to JUMPSTART YOUR IMMUNE SYSTEM to attack YoUr advanced PROSTATE CANCER Starting your treatment with For more information, visit www.provenge.com Please see inside front cover and page 6 for
More informationThe effect of early versus delayed radiation therapy on length of hospital stay in the palliative setting
Original Article on Palliative Radiotherapy The effect of early versus delayed radiation therapy on length of hospital stay in the palliative setting Taylor R. Cushman 1, Shervin Shirvani 2, Mohamed Khan
More informationMedication is injected into your bladder to encourage your immune system to attack and destroy the cancer cells.
BCG Surgery What does it entail? Medication is injected into your bladder to encourage your immune system to attack and destroy the cancer cells. Your bladder will be removed and replaced, either with:
More informationTherapeutic ratio - An Overview. Past Present Future Prof Ramesh S Bilimaga
Therapeutic ratio - An Overview Past Present Future Prof Ramesh S Bilimaga Radiation Oncology Discipline of human medicine concerned with the generation, conservation and dissemination of knowledge concerning
More information22 Week ADVANCED MARATHON TRAINING PLAN
RG Active 22 Week Advanced Marathon Training Plan Page 1 22 Week ADVANCED MARATHON TRAINING PLAN [Type www.bloodwise.org.uk here] Introduction Below is a 22 week advanced marathon training plan to help
More informationWhat s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM
What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM Covering: Basic Definition New assessment criteria Some newer treatments BiPAP Not Covering: Definitions: Chronic Obstructive Pulmonary
More informationHyperbaric Oxygen Pressurization (HBO)
Hyperbaric Oxygen Pressurization (HBO) Policy Number: Original Effective Date: MM.02.012 04/15/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2018 Section: Medicine
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationTransplant and Dialysis Information
Transplant and Dialysis Information Dialysis and Transplant Information This document is intended to be an easy-to-read guide to help patients, families and friends understand the options when addressing
More informationProspect. *Entry level* *No equipment required* *12 weeks* December 2018 (1 st Ed.)
Prospect *Entry level* *No equipment required* *12 weeks* WHAT IS PROSPECT? Prospect is our exercise program for the absolute beginner with little to no experience doing ANY kind of a formal exercise program,
More informationCleveland Clinic Multispecialty Pathology Symposium
Robert J. Tomsich Pathology & Laboratory Medicine Institute Laboratories Multispecialty Pathology Symposium January 19-21, 2018 The Cosmopolitan of Las Vegas Las Vegas, NV SAMs credit available Register
More informationThe Welsh Liberal Democrats plan to provide an effective cancer strategy for Wales
Wales Can Tackle Cancer: The Welsh Liberal Democrats plan to provide an effective cancer strategy for Wales Index Page One : Foreword Page Two: No Comprehensive Caner Plan in Wales Page Three: IMRT - Wales
More informationDr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah
Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss
More informationHyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy Policy Number: 2.01.04 Last Review: 11/2017 Origination: 10/1988 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for oxygen
More informationFrequently Asked Questions
Ida Orengo, M.D. Mohsin Mir, M.D. Department of Dermatology 1977 Butler Boulevard, Suite E6.200 Houston, TX 77030 (713) 798-6925 / (713) 798-6624 telephone (713) 798-5535 fax Frequently Asked Questions
More informationAbout this consent form
Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:
More informationHyperbaric Oxygen Therapy. Description
Subject: Hyperbaric Oxygen Therapy Page: 1 of 28 Last Review Status/Date: December 2014 Hyperbaric Oxygen Therapy Description Hyperbaric oxygen therapy (HBO) involves breathing 100% oxygen at a pressure
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More informationOxygen and Oxygen Equipment
Oxygen and Oxygen Equipment I. Policy University Health Alliance (UHA) will reimburse for home oxygen and oxygen equipment when it is determined to be medically necessary and when it meets the medical
More informationPatient Education Kidney Early Education Program (KEEP) Chapter 2 bjectives: Overview 1. Understand what kidneys do. 2. Understand symptoms
Patient Education (KEEP) Chapter 2 What Your Kidneys Do And what happens when they fail Objectives: 1. Understand what kidneys do. 2. Understand symptoms of uremia and some ways to treat it. 3. Know the
More information10425 N. Central Expressway Dallas, TX o f
10425 N. Central Expressway Dallas, TX 75231 o. 214.954.7734 f. 469.250.4299 The Radiation Therapy Process: Image-Guided, Intensity-Modulated Radiation Therapy (IG-IMRT) We suggest you read through this
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationTHE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant
Dysphagia THE POTENTIAL IMPACT OF VITALSTIM THERAPY ON HEALTHCARE COSTS: A White PaperVitalStim Therapy has significant Contents potential to dramatically impact the health care costs arising from oropharyngeal
More informationHyperbaric oxygen for delayed radiation injuries.
UHM 2004, Vol. 31, No.1 - HBO 2 for delayed radiation injuries Hyperbaric oxygen for delayed radiation injuries. J.J. FELDMEIER Toledo Radiation Oncology and the Medical College of Ohio, Toledo, Ohio INTRODUCTION
More information14 Week BEGINNER MILE CYCLING TRAINING PLAN
RG Active 14 Week Beginner 60-100mile Cycling Training Plan Page 1 14 Week BEGINNER 60-100MILE CYCLING TRAINING PLAN RG Active 14 Week Beginner 60-100mile Cycling Training Plan Page 2 The NSPCC has teamed
More informationConsequences of cancer treatments
Consequences of cancer treatments Karen Morgan Macmillan Consultant Radiographer 18 th July 2014 Background - UK / year Macmillan facts and figures 2 million are living with consequences of cancer treatment
More informationCHALLENGING HABIT: PLANNING AND PREPARATION, THE ART OF PERIODISATION AND OPTIMISING PERFORMANCE. By Matthew Wyon
CHALLENGING HABIT: PLANNING AND PREPARATION, THE ART OF PERIODISATION AND OPTIMISING PERFORMANCE By Matthew Wyon A question to start - what is the goal, raison d etre of a dance company? Hopefully you
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationMedicare Protocols and Procedures By Dr. Ron Short, DC, MCS-P
Medicare Protocols and Procedures By Dr. Ron Short, DC, MCS-P Intake (Initial Visit) At the initial visit you need to gather specific information in the history that Medicare requires. You need to inform
More informationPost-Lumpectomy Radiation Techniques and Toxicities
Post-Lumpectomy Radiation Techniques and Toxicities Laura Willson, MD Abbott Northwestern Hospital Dept. of Radiation Oncology February 2, 2019 Learning Objectives How radiation therapy works Standard
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationFacilitator Application CA Training
Page 1 of 5 Facilitator Application CA Training Note: Please fill out the application completely. Date of the training: City where training will be held: Contact Information: Last Name: First Name: M.I.:
More information16 Week BEGINNER 100MILE CYCLING TRAINING PLAN
RG Active 16 Week Beginner 100mile Cycling Training Plan Page 1 16 Week BEGINNER 100MILE CYCLING TRAINING PLAN RG Active 16 Week Beginner 100mile Cycling Training Plan Page 2 The NSPCC has teamed up with
More informationImpact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length of Stay in Laparoscopic Colorectal Surgeries
Journal of Pharmacy and Pharmacology 4 (2016) 521-525 doi: 10.17265/2328-2150/2016.10.001 D DAVID PUBLISHING Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length
More informationA GUIDE TO STARTING TREATMENT
A GUIDE TO STARTING TREATMENT Please see accompanying and Medication Guide. full Prescribing IDHIFA (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an
More informationOxygen and Oxygen Equipment
Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013 Section: DME Place(s) of Service: Home I.
More informationCrush Injury. Professeur D. MATHIEU. Medicine
Crush Injury Professeur D. MATHIEU Department of Critical Care and Hyperbaric Medicine University Hospital of Lille - France Definitions Crush Injury An injury sustained when a body part is subjected to
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationSTAMPS HEALTH SERVICES Allergy Injection Information
Allergy Injection Information Phone: (404) 385-4995 Fax: (404) 894-6254 Website: www.health.gatech.edu Hours of Operation: Monday, Tuesday, Wednesday, & Friday 8-3 Thursdays: 9-3 1. All students requesting
More informationTABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
More information2.0 Synopsis. Adalimumab R&D/04/118. (For National Authority Use Only) Referring to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Title of Study: Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More information14 Week BEGINNER HALF MARATHON (21km) TRAINING PLAN
RG Active 14 Week Beginner Half-Marathon Training Plan Page 1 14 Week BEGINNER HALF MARATHON (21km) TRAINING PLAN RG Active 14 Week Beginner Half-Marathon Training Plan Page 2 The NSPCC has teamed up with
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationDemand Regarding Enbrel (Etanercept)
July 1, 2009 Mr. Yoichi Masuzoe, Minister of Health, Labour, and Welfare Mr. Kazuhiko Mori, Director, Safety Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Mr.
More informationNEUROCARE 1000/4P NEUROMUSCULAR ELECTRIC STIMULATOR FOR DIABETIC NEUROPATHY TREATMENT
NEUROCARE 1000/4P NEUROMUSCULAR ELECTRIC STIMULATOR FOR DIABETIC NEUROPATHY TREATMENT Diabetic neuropathies are common in almost 50 percent of all sufferers. Although current studies still don t pinpoint
More informationOxygen and Oxygen Equipment
Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: DME Place(s) of Service:
More informationReview Session!1
Review Session!1 Review Four types of variables: nominal ordinal interval ratio score Values of variables are distributed Important goal: characterizing the distribution Graphs Bar graphs for nominal variables
More informationHyperbaric Oxygen Therapy. Description
Subject: Hyperbaric Oxygen Therapy Page: 1 of 29 Last Review Status/Date: March 2017 Hyperbaric Oxygen Therapy Description Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen at a pressure
More informationPATIENT ENTRANCE FORM
PATIENT ENTRANCE FORM Name _ Date Address City/ Province Postal Code Home Telephone Work Telephone Email Address Would like email reminders for appointments? Yes No Date of Birth (Day/Month/Year) Age Marital
More informationSchweizer Register für Neuroendokrine Tumore Le Registre Suisse des tumeurs neuroendocrines Registro Svizzero per i Tumori Neuroendocrini
Introduction Gastroenteropancreatic Neuroendocrine tumors (NETs) have a low incidence: overall more than 5/100 000. The significant growing incidence has been attributed to diagnostic tools (endoscopy,
More informationEvaluator. the. CSCE President s Report November Content
the Evaluator Content CSCE President s Report 1 The MIG-can one size fit all? 2 The MIG, it is a Guideline? 3 The MIG: a Common Treatment Pathway and Funding Model 4 The MIG - A Work in Progress 5 The
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More information04 Chapter Four Treatment modalities. Experience does not err, it is only your judgement that errs in expecting from her what is not in her power.
Chapter Four Treatment modalities Experience does not err, it is only your judgement that errs in expecting from her what is not in her power. LEONARDO da Vinci Vol 2 esrd Ch pg 29 Contents 22 Incident
More informationProstate Artery Embolisation (PAE)
Service: Imaging Prostate Artery Embolisation (PAE) Exceptional healthcare, personally delivered Ask 3 Questions The team delivering your healthcare want to encourage you to become as involved as possible
More informationThe Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.
The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain
More informationRadiation Treatment. A Guide for Patients and Their Families
Radiation Treatment A Guide for Patients and Their Families Introduction This booklet serves as a guide and covers information on radiation treatment, its procedures and general side effects during treatment.
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationPersonal Fitness Plan [Type the document subtitle] 3/10/2014 Class Period MW T/TH
Personal Fitness Plan [Type the document subtitle] 3/10/2014 Class Period MW T/TH MY PERSONAL FITNESS PLAN CONTRACT Fitness Contract for Self I,, am going to make a commitment to helping build lifelong
More informationRadiotherapy for lymphoma
Radiotherapy for lymphoma The name of your consultant is: The radiographer who explained the treatment to you is: You can contact us on: What is radiotherapy? Radiotherapy treats cancer by using high energy
More information